HomeDRREDDY • NSE
add
Dr Reddy's Laboratories Ltd
Previous close
₹1,195.35
Day range
₹1,193.60 - ₹1,223.20
Year range
₹1,074.00 - ₹1,421.49
Market cap
1.01T INR
Avg Volume
1.48M
P/E ratio
18.96
Dividend yield
0.66%
Primary exchange
NSE
In the news
Financials
Income Statement
Revenue
Net income
(INR) | Sep 2024info | Y/Y change |
---|---|---|
Revenue | 80.16B | 16.51% |
Operating expense | 29.72B | 24.54% |
Net income | 12.55B | -15.18% |
Net profit margin | 15.66 | -27.20% |
Earnings per share | 15.83 | -11.13% |
EBITDA | 22.02B | 8.53% |
Effective tax rate | 30.01% | — |
Balance Sheet
Total assets
Total liabilities
(INR) | Sep 2024info | Y/Y change |
---|---|---|
Cash and short-term investments | 63.07B | -7.15% |
Total assets | 465.96B | 34.27% |
Total liabilities | 156.67B | 66.79% |
Total equity | 309.28B | — |
Shares outstanding | 833.05M | — |
Price to book | 3.26 | — |
Return on assets | 10.24% | — |
Return on capital | 13.21% | — |
Cash Flow
Net change in cash
(INR) | Sep 2024info | Y/Y change |
---|---|---|
Net income | 12.55B | -15.18% |
Cash from operations | 9.32B | -48.03% |
Cash from investing | -19.07B | -322.21% |
Cash from financing | 16.15B | 329.53% |
Net change in cash | 6.37B | 1.03% |
Free cash flow | 3.92B | -72.47% |
About
Dr. Reddy's Laboratories is an Indian multinational pharmaceutical company based in Hyderabad. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology.
Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to other less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe.
By 2007, Dr. Wikipedia
CEO
Founded
1984
Headquarters
Website
Employees
27,048